KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Current Taxes (2016 - 2026)

Abbott Laboratories' Current Taxes history spans 18 years, with the latest figure at $598.0 million for Q1 2026.

  • On a quarterly basis, Current Taxes rose 23.3% to $598.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $598.0 million, a 23.3% increase, with the full-year FY2025 number at $569.0 million, down 4.21% from a year prior.
  • Current Taxes hit $598.0 million in Q1 2026 for Abbott Laboratories, up from $569.0 million in the prior quarter.
  • Over the last five years, Current Taxes for ABT hit a ceiling of $713.0 million in Q3 2024 and a floor of $273.0 million in Q2 2023.
  • Historically, Current Taxes has averaged $460.5 million across 5 years, with a median of $469.0 million in 2025.
  • Biggest five-year swings in Current Taxes: surged 124.21% in 2024 and later crashed 35.11% in 2025.
  • Tracing ABT's Current Taxes over 5 years: stood at $343.0 million in 2022, then soared by 43.44% to $492.0 million in 2023, then increased by 20.73% to $594.0 million in 2024, then dropped by 4.21% to $569.0 million in 2025, then rose by 5.1% to $598.0 million in 2026.
  • Business Quant data shows Current Taxes for ABT at $598.0 million in Q1 2026, $569.0 million in Q4 2025, and $469.0 million in Q3 2025.